AbbVie (NYSE:ABBV) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

AbbVie (NYSE:ABBV) had its target price hoisted by Cantor Fitzgerald from $285.00 to $290.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 6.87% from the stock’s current price.

A number of other brokerages have also commented on ABBV. Rothschild & Co Redburn lifted their price target on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Guggenheim upped their price objective on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Scotiabank lifted their target price on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a research report on Tuesday. UBS Group restated a “neutral” rating on shares of AbbVie in a research report on Tuesday. Finally, Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $276.11.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $271.37 on Thursday. AbbVie has a one year low of $190.75 and a one year high of $274.94. The company has a market cap of $479.44 billion, a price-to-earnings ratio of 76.66, a PEG ratio of 1.22 and a beta of 0.24. The firm has a 50 day simple moving average of $258.27 and a 200 day simple moving average of $235.87.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie will post 13.93 EPS for the current year.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AbbVie

A number of hedge funds have recently added to or reduced their stakes in ABBV. Ranch Capital Advisors Inc. increased its position in shares of AbbVie by 37.0% during the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after acquiring an additional 4,017 shares in the last quarter. Capital Advisors Inc. OK boosted its position in shares of AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after buying an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of AbbVie during the second quarter valued at $23,557,000. Wedge Capital Management L L P NC increased its holdings in AbbVie by 7.5% in the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after buying an additional 9,380 shares in the last quarter. Finally, Mission Wealth Management LP increased its holdings in AbbVie by 119.1% in the 2nd quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock worth $17,376,000 after buying an additional 37,531 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA granted two Breakthrough Therapy Designations to AbbVie’s investigational cancer drug telisotuzumab adizutecan (Temab-A/ABBV-400), covering colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, strengthening the company’s oncology pipeline and ADC portfolio. They do not represent an approval, but investors viewed the news favorably. AbbVie Temab-A FDA Breakthrough Designations
• Positive Sentiment: AbbVie and Genmab reported that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 success could expand Epkinly’s commercial opportunity and position it as a stronger competitor to Roche’s Polivy. AbbVie Epkinly Phase 3 Results
• Positive Sentiment: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating, implying continued upside based on the company’s pipeline and earnings outlook. Scotiabank Raises AbbVie Price Target
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors may remain focused on operating performance, guidance, and progress in replacing Humira-related revenue ahead of the release. AbbVie Upcoming Earnings
• Negative Sentiment: One analysis highlighted AbbVie’s reported payout ratio of roughly 190%, arguing that the dividend exceeds accounting earnings and could raise concerns about long-term sustainability. This is a risk for income-focused investors, although the measure can be affected by noncash charges and does not by itself indicate an imminent dividend cut. AbbVie Dividend Payout Analysis

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.